Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021858 | 0.96 | DPP4 (0.37) | DPP4ELANEANPEPLAP3DPP8 | |
| SCHEMBL7031488 | 0.95 | DPP4 (0.36) | DPP4ELANEANPEPLAP3DPP8 | |
| SCHEMBL7031540 | 0.73 | SRC (0.38) | ELANEANPEPLAP3SRCBTN3A1 | |
| SCHEMBL643837 | 0.73 | BTN3A1 (0.40) | ELANEANPEPLAP3SRCBTN3A1 | |
| SCHEMBL5996997 | 0.73 | BTN3A1 (0.40) | ELANEANPEPLAP3SRCBTN3A1 | |
| SCHEMBL5857844 | 0.72 | ELANE (0.40) | ELANEANPEPLAP3SRCBTN3A1 | |
| SCHEMBL27554232 | 0.72 | ANPEP (0.36) | ELANEANPEPLAP3SRCBTN3A1 | |
| SCHEMBL7025497 | 0.72 | ANPEP (0.36) | ELANEANPEPLAP3SRCBTN3A1 | |
| SCHEMBL7021900 | 0.71 | DPP4 (0.36) | DPP4ELANEANPEPLAP3DPP8 | |
| SCHEMBL7021781 | 0.71 | DPP7 (0.39) | DPP4ELANEDPP8BTN3A1PRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | DPP4 250/4885ELANE 3126/4885ANPEP 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.